HIV Entry and Its Inhibition

[1]  D. Littman.  Chemokine Receptors: Keys to AIDS Pathogenesis? , 1998, Cell.

[2]  C. Weiss,et al.  Capture of an early fusion-active conformation of HIV-1 gp41 , 1998, Nature Structural Biology.

[3]  Benedikt Westermann,et al.  SNAREpins: Minimal Machinery for Membrane Fusion , 1998, Cell.

[4]  D. Bolognesi,et al.  HIV vaccines: Viral envelope fails to deliver? , 1998, Nature.

[5]  A. Trkola,et al.  Immunological and Virological Analyses of Persons Infected by Human Immunodeficiency Virus Type 1 while Participating in Trials of Recombinant gp120 Subunit Vaccines , 1998, Journal of Virology.

[6]  T. Matthews,et al.  Determinants of Human Immunodeficiency Virus Type 1 Resistance to gp41-Derived Inhibitory Peptides , 1998, Journal of Virology.

[7]  S. Durell,et al.  Dilation of the Human Immunodeficiency Virus–1 Envelope Glycoprotein Fusion Pore Revealed by the Inhibitory Action of a Synthetic Peptide from gp41 , 1998, The Journal of cell biology.

[8]  R. Blumenthal,et al.  Conformational Changes in Cell Surface HIV-1 Envelope Glycoproteins Are Triggered by Cooperation between Cell Surface CD4 and Co-receptors* , 1998, The Journal of Biological Chemistry.

[9]  P S Kim,et al.  Influenza hemagglutinin is spring-loaded by a metastable native conformation. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[10]  Christos,et al.  Inhibition of HIV type 1 infectivity by constrained alpha-helical peptides: implications for the viral fusion mechanism. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[11]  D. Burton.  A vaccine for HIV type 1: the antibody perspective. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[12]  F. Hughson.  Enveloped viruses: A common mode of membrane fusion? , 1997, Current Biology.

[13]  S. Harrison,et al.  Atomic structure of the ectodomain from HIV-1 gp41 , 1997, Nature.

[14]  B. Haynes.  HIV vaccines: where we are and where we are going , 1996, The Lancet.

[15]  J. Mascola,et al.  Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. , 1996, The Journal of infectious diseases.

[16]  R. Redfield,et al.  Lack of induction of antibodies specific for conserved, discontinuous epitopes of HIV-1 envelope glycoprotein by candidate AIDS vaccines. , 1995, Journal of immunology.

[17]  Stephen C. Blacklow,et al.  A trimeric structural domain of the HIV-1 transmembrane glycoprotein , 1995, Nature Structural Biology.

[18]  T. Matthews,et al.  Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[19]  Shibo Jiang,et al.  HIV-1 inhibition by a peptide , 1993, Nature.

[20]  P. S. Kim,et al.  A spring-loaded mechanism for the conformational change of influenza hemagglutinin , 1993, Cell.

[21]  J Ginsburg,et al.  Looking Ahead , 2011, Metabolism: clinical and experimental.